-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target

Benzinga·10/02/2026 10:48:01
Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.